Oncology

Latest News

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com

Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

By AJMC Contributor

May 12th 2025

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 12th 2014

Merck Serono to Halt Stage III NSCLC Trial With Tecemotide

Tecemotide, a synthetic lipopeptide immunotherapy was being developed as a cancer vaccine against the MUC1 glycoprotein that is often aberrantly overexpressed in NSCLC.

September 12th 2014

CMS's Open Payments Database on Schedule for Launch

Despite reported glitches, CMS plans to launch the database that will provide information on payments for research, gifts, meals, or speaker fees received by providers and teaching hospitals from the pharmaceutical industry.

September 11th 2014

In The Literature: MicroRNAs As Markers of Cancer Risk, Based on Ethnicity

The study, published in BMC Medical Genomics, identified ethnicity-based variability in microRNA expression that could lead to health disparities in cancer across the globe.

September 11th 2014

Study Evaluating Clinical Trial Bias in Pharma Presents Encouraging Evidence

The study, which evaluated the top 20 pharmaceutical companies, identified Amgen, AstraZeneca, and Celgene as the most dedicated to clinical trial data sharing.

September 11th 2014

NanoString Announces New PanCancer Immune Panel

The panel, developed in collaboration with immunooncology scientists around the world, including at INSERM, will help researchers create a profile of the human immune response in all cancer types.

September 11th 2014

Extended Use of Xtandi in Chemothrerapy-NaÃ¯ve Prostate Cancer Patients

The FDA approval will greatly influence the reach of the drug which was approved for use in advanced prostate cancer patients.

September 10th 2014

Watchful Waiting in Prostate Cancer: Role of Ethnicity

The retrospective study, conducted at the Thomas Jefferson University in Philadelphia, found that watchful waiting among black men with early stage prostate cancer who had undergone surgery, resulted in a more aggressive disease.

September 9th 2014

Androgen-Deprivation is Essential in Prostate Cancer Regimen

A joint statement by ASCO and CCO published new guidelines in the treatment of metastatic CRPC.

September 9th 2014

NICE Rejects Abraxane for Pancreatic Cancer

NICE does not deem Abraxane more effective than FOLFIRINOX, in addition to the fact that it causes severe side effects.

September 9th 2014

AACR's Policy Statement Urges FDA-Regulation of Laboratory-Developed Tests

The statement points to the increased complexity of some of the LDTs and highlights patient safety issues that are at stake.

September 9th 2014

DEA Moves to Curtail Drug Abuse

With the objective of reducing drug abuse, especially by teenagers, the D.E.A. will now allow patients and their relatives to mail-in their unneeded stockpiles of prescription drugs back to the pharmacies.

September 9th 2014

Global Study Identifies Prediabetes as a Risk Factor for Cancer

A meta-analysis comprising 16 studies and 891,426 participants from various regions of the world shows that prediabetes increases the risk of cancer by 15%, with differing risks depending on the type of cancer.

September 8th 2014

Genomic Analysis Determines Post-Surgery Treatment in Prostate Cancer

The results of the genomic data can guide treatment decisions post-surgery in prostate cancer.

September 5th 2014

Family History Alone May Not Tell the Tale in Jewish Women

Although family history is a risk factor, a new study has shown that it should not be the primary determinant of mutation screening for breast and ovarian cancer.

September 5th 2014

Smoke-Free Homes Now the Overwhelming Norm, Even in Tobacco States, CDC Reports

Mary K. Caffrey

Growing up in a smoke-free home is now the overwhelming norm for most Americans, with the share of smoke-free homes nearly doubling in the 20 years that ended in 2011, the Centers for Disease Control and Prevention said today in a new study. Overall, the prevalence of smoke-free home rules increased from 43 percent during 1992—1993 to 83 percent during 2010—2011, according to the study, which appears in today's Mortality and Morbidity Weekly Report, published by CDC.

September 5th 2014

Fee-For-Service May Introduce Treatment Bias in Radiation Oncology

The write believes that the episodic reimbursement model might introduce bias among radiation oncologists who own their own treatment equipment.

September 5th 2014

Effects of Multidisciplinary Team Care on Utilization of Emergency Care for Patients With Lung Cancer

Shun-Mu Wang, MHA Pei-Tseng Kung, ScD Yueh-Hsin Wang, MHA Kuang-Hua Huang, PhD Wen-Chen Tsai, DrPH

Impact of multidisciplinary team care on reducing utilization of emergency department visits for patients with lung cancer.

September 4th 2014

Perspective: The Value of Care and QALY

Does $50,000 per quality-adjusted life year (QALY) hold value in today's age of high-priced specialty drugs? The authors evaluate this yardstick and recommend changes that could aid cost-effectiveness decisions.

September 4th 2014

What Will Drive the Expected Rise in US Healthcare Spending?

Mary K. Caffrey

Yesterday's government report that healthcare spending will start rising faster after a decade of historically slow growth raises questions: Will rising numbers of insured people drive the spending? Or are healthcare costs going up on their own? The answer is likely some of each, based on a look at trends within yesterday's report and a just-released study of spending by commercial health plans, published in The American Journal of Managed Care.

September 4th 2014

Pembrolizumab Approved For Advanced Melanoma

Following a breakthrough therapy designation, pembrolizumab was included in FDA's accelerated approval program to allow early patient access.

September 4th 2014

Opdivo Reignites the Drug Pricing Discussion

While Sovaldi is still fresh on the mind, Ono Pharmaceutical's Opdivo (nivolumab), marketed jointly with BMS in Japan, has analysts projecting what the treatment might cost in the US.

September 3rd 2014

JAMA Study Does Not Find Improved Survival With Double Mastectomy

Survival at 10 years was no better when women had double mastectomies.

September 3rd 2014

ASCO Updates Clinical Guidelines for HER2-Negative Breast Cancer

The guidelines suggest various treatment options available, following consideration of the patient's status and preference.

September 3rd 2014

Halozyme's PEGPH20 Receives Fast-Track Designation

The program is being developed to treat metastatic prostate cancer.

ASCO President Dr Peter P. Yu Defines Value in Cancer Care

September 3rd 2014

ASCO President Dr Peter P. Yu Defines Value in Cancer Care

Dr Peter P. Yu, MD, Emphasized the importance of value when considering the implications of cancer care.

September 3rd 2014

American Lung Association Applauds CVS: Tobacco Products are Off the Shelf

CVS accelerated its timeline from October to September to stop selling tobacco and related products in its retail stores.

September 2nd 2014

Cabozantinib Fails in Phase 3

The company developing the drug, Excelis, now plans to focus it's attention on the ongoing kidney and liver cancer trials for the drug.

September 2nd 2014

Opioid Abuse and Cancer: The Patient's Perspective

Concerns about addiction and abuse may prevent patients from informing their oncologist about their level of pain.

August 30th 2014

AJMC Series Finds Positive Spin-offs for Cancer Care From New Jersey's Higher Education Overhaul

Status in the States, the series in The American Journal of Managed Care's news publication, Evidence-Based Oncology, took a look at cancer care in New Jersey two years after a high-profile reorganization of the state's higher education system. The overhaul has improved collaboration within research units and with nearby pharmaceutical giants, and a new medical school reports a bumper crop of applicants.

August 29th 2014

MolecularHealth Offers a Reimbursement Calculator

The tool is aimed to provide decision-support to both patients and physicians while considering their reimbursement information.

...

152 153 154 155 156 157 158 159 160

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions